<span item_type="fundamental" item_id="f2e7cede9705562a61aa8a9d2964b0f9" counter_id="ST/US/FBIOP" env="prod"></span><span item_type="announcement" item_id="549445118286759425" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 16.41 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD 0.45.</p><p></p><h3>Cash and Cash Equivalents</h3><ul><li>As of June 30, 2025, Fortress Biotech’s consolidated cash and cash equivalents totaled $74.4 million, an increase of $17.1 million from $57.3 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li></ul><h3>Segment Revenue</h3><ul><li>Journey Medical’s net product revenues for the second quarter ended June 30, 2025, were $15.0 million, compared to $14.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li><li>Fortress Biotech’s consolidated net revenue totaled $16.4 million for the second quarter ended June 30, 2025, compared to $14.9 million for the second quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Consolidated research and development expenses were $8.1 million for the second quarter ended June 30, 2025, compared to $12.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li><li>Consolidated selling, general and administrative costs were $38.8 million for the second quarter ended June 30, 2025, compared to $20.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li><li>Consolidated net income attributable to common stockholders was $13.4 million, or $0.50 per share basic, and $0.45 per share diluted, for the second quarter ended June 30, 2025, compared to a net loss of - $13.3 million, or - $0.73 per share basic and diluted, for the second quarter ended June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Fortress Biotech anticipates the PDUFA goal date for CUTX-101 on September 30, 2025, and the potential issuance of a Priority Review Voucher upon approval.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li><li>The company plans to advance MB-101, in combination with MB-108, as a potential treatment option for high-grade gliomas.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li><li>Journey Medical continues to expand payer coverage for Emrosi™, now reaching 65% of U.S. commercial lives.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm"></span></li></ul>

Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q2 Revenue: USD 16.41 M